AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Tianjin Medical University

Status and phase

Not yet enrolling

Phase 2

Conditions

Pancreatic Cancer, Adult

Treatments

Drug: AG regimen

Drug: Nimotuzumab

Study type

Interventional

Funder types

Other

Identifiers

NCT06938503

IST-PC-202501

Details and patient eligibility

About

This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel/gemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).

Full description

This clinical study is designed as a prospective, open-label, single arm study to evaluate the clinical efficacy and safety of nab-paclitaxel/gemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. This study is divided into two stages: in stage I, all patients will receive 4 cycles of nab-paclitaxel/gemcitabine (AG regimen, 3 weeks as a cycle) and nimotuzumab. Imaging reexamination will be conducted 12 weeks later. In stage II, patients who are without disease progression (PD) will receive irreversible electroporation ablation and at least 3 cycles of adjuvant treatment (AG and nimotuzumab). If the imaging evaluation shows disease progression (PD), then the subsequent treatment will be changed to the standard treatment in hospital. The main endpoint is overall survival (OS). Additional end points included progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), safety, etc.

Enrollment

48 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

1. Age 18-75 years old, gender unlimited;
1. Histologically or cytologically confirmed pancreatic cancer;
1. Confirmed as locally advanced pancreatic cancer by CT/MRI imaging, with no evidence of distant metastasis;
1. No prior chemotherapy or other tumor systemic therapy;
1. Measurable disease according to RECIST criteria v1.1;
1. Adequate organ and bone marrow function, defined as follows: hemoglobin≥9.0 g/dL; absolute neutrophil count (ANC)≥1.5×10^9/L; platelets≥100×10^9/L; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance > 60 mL/min;
1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 2;
1. Life expectancy is expected to be ≥3 months;
1. Fertile subjects are willing to take contraceptive measures during the study period.
1. Good compliance and signed informed consent voluntarily.

Exclusion criteria

1. Refuse chemotherapy or surgery;
1. Other part (e.g. peritoneum, lung, bone, brain) metastasis;
1. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
1. Accompanied by other serious diseases, including but not limited to: compensatory heart failure (NYHA grade III and IV), unstable angina, poorly controlled arrhythmias, uncontrolled hypertension (SBP>160mmHg or DBP>100mmHg); active infections; unmanageable diabetes mellitus; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency;
1. Undergone major surgery within 30 days;
1. Participated in other drug related clinical trials within 4 weeks;
1. Known allergy to prescription or any component of the prescription used in this study;
1. With HIV, or active hepatitis (hepatitis B, hepatitis C);
1. Failure to recover from treatment-related toxicity to ≤ grade 1 (adverse events such as alopecia judged by the researcher not to affect the treatment with the research drug are excluded);
10.Other reasons that are not suitable to participate in this study according to the researcher's judgment.